Compare Stocks: ZYME, ALKS, IMVT, and KNSA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$41.22 +2.8%	$45.17	$27.00 ▼ $55.67	$6.92B	0.32	2.15 million shs	3.41 million shs
IMVT Immunovant	$26.73 -2.8%	$37.55	$17.02 ▼ $45.42	$5.52B	0.84	1.52 million shs	1.46 million shs
KNSA Kiniksa Pharmaceuticals International	$78.59 -1.7%	$77.82	$35.20 ▼ $82.98	$6.13B	0.04	678,740 shs	524,790 shs
ZYME Zymeworks	$25.03 -2.8%	$26.83	$16.00 ▼ $31.34	$1.78B	1.17	727,229 shs	632,723 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+2.61%	-0.02%	-12.88%	-23.94%	+24.42%
IMVT Immunovant	-1.40%	-9.09%	-24.94%	-31.67%	+53.43%
KNSA Kiniksa Pharmaceuticals International	+1.40%	+1.51%	+6.37%	+25.00%	+105.71%
ZYME Zymeworks	+3.96%	+1.94%	-1.15%	+6.45%	+38.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$41.22 +2.8%	$45.17	$27.00 ▼ $55.67	$6.92B	0.32	2.15 million shs	3.41 million shs
IMVT Immunovant	$26.73 -2.8%	$37.55	$17.02 ▼ $45.42	$5.52B	0.84	1.52 million shs	1.46 million shs
KNSA Kiniksa Pharmaceuticals International	$78.59 -1.7%	$77.82	$35.20 ▼ $82.98	$6.13B	0.04	678,740 shs	524,790 shs
ZYME Zymeworks	$25.03 -2.8%	$26.83	$16.00 ▼ $31.34	$1.78B	1.17	727,229 shs	632,723 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+2.61%	-0.02%	-12.88%	-23.94%	+24.42%
IMVT Immunovant	-1.40%	-9.09%	-24.94%	-31.67%	+53.43%
KNSA Kiniksa Pharmaceuticals International	+1.40%	+1.51%	+6.37%	+25.00%	+105.71%
ZYME Zymeworks	+3.96%	+1.94%	-1.15%	+6.45%	+38.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.68	Moderate Buy	$54.47	34.20% Upside
IMVT Immunovant	2.58	Moderate Buy	$44.00	63.84% Upside
KNSA Kiniksa Pharmaceuticals International	2.89	Moderate Buy	$93.14	19.97% Upside
ZYME Zymeworks	2.77	Moderate Buy	$40.64	58.59% Upside

Current Analyst Ratings Breakdown

Latest ZYME, ALKS, IMVT, and KNSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	ALKS Alkermes	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$55.00
10/15/2026	ZYME Zymeworks	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/8/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/7/2026	ZYME Zymeworks	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$32.00 ➝ $34.00
10/2/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/30/2026	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$87.00
9/29/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$38.00 ➝ $39.00
9/29/2026	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$34.00
9/24/2026	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Positive
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	$50.00

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.67B	4.08	$1.74 per share	23.34	$11.02 per share	3.68
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$677.56M	8.94	$0.78 per share	99.32	$7.44 per share	10.44
ZYME Zymeworks	$105.96M	17.16	N/A	N/A	$3.59 per share	7.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	106.88	169.13	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	80.05	37.51	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	25.37	N/A	-405.31%	-72.30%	-37.18%	11/5/2026 (Estimated)

Latest ZYME, ALKS, IMVT, and KNSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q2 2027	IMVT Immunovant	-$0.73	N/A	N/A	N/A	$7.10 million	N/A
11/5/2026	Q3 2026	ZYME Zymeworks	$2.29	N/A	N/A	N/A	$227.39 million	N/A
10/28/2026	Q3 2026	ALKS Alkermes	-$0.0788	N/A	N/A	N/A	$463.35 million	N/A
10/27/2026	Q3 2026	KNSA Kiniksa Pharmaceuticals International	$0.3722	N/A	N/A	N/A	$260.22 million	N/A
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
IMVT Immunovant	N/A	7.27	7.27
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
IMVT Immunovant	47.08%
KNSA Kiniksa Pharmaceuticals International	53.95%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
IMVT Immunovant	1.90%
KNSA Kiniksa Pharmaceuticals International	51.98%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable
ZYME Zymeworks	264	70.96 million	47.18 million	N/A

ZYME, ALKS, IMVT, and KNSA Headlines

Recent News About These Companies

Zymeworks Sets Q3 2026 Results Date and Ramps Up Investor Conference Presence

October 15 at 6:51 AM | tipranks.com

Zymeworks Announces Third Quarter 2026 Financial Results Date and Upcoming Investor Conference Participation

October 15 at 6:30 AM | quiverquant.comQ

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

October 15 at 6:10 AM | financialpost.comF

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

October 15 at 6:00 AM | globenewswire.com

Zymeworks Inc. (ZYME) - What Are Researchers Thinking About This Stock?

October 15 at 4:28 AM | marketbeat.com

Zymeworks (NASDAQ:ZYME) EVP Sells $357,557.20 in Stock

October 12, 2026 | americanbankingnews.com

Zymeworks Officer Adam Schayowitz Files to Sell 13,832 RSU Shares Valued at $349K

October 11, 2026 | kalkinemedia.comK

Zymeworks (NASDAQ:ZYME) EVP Adam Schayowitz Sells 13,832 Shares of Company Stock

October 10, 2026 | insidertrades.com

Zymeworks (NASDAQ:ZYME) Stock: Insider Adam Schayowitz Sells 13,832 Shares

October 9, 2026 | marketbeat.com

Zymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO Hire

October 9, 2026 | finance.yahoo.com

Zymeworks (NASDAQ:ZYME) Stock Price Up 4.4% - Should You Buy?

October 7, 2026 | marketbeat.com

Zymeworks stock gains 4.85 percent after 2026 outlook update

October 5, 2026 | ad-hoc-news.deA

Zymeworks stock fell 3.12 percent after Theravance deal closes

October 4, 2026 | ad-hoc-news.deA

Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

October 2, 2026 | marketbeat.com

Copertura su Zymeworks ripristinata con Buy da TD Cowen sull’acquisizione

September 29, 2026 | it.investing.com

Zymeworks (NASDAQ:ZYME) Stock Rated "Buy" in New Coverage at TD Cowen

September 29, 2026 | marketbeat.com

Zymeworks raises 2026 guidance after closing Theravance acquisition

September 28, 2026 | streetinsider.com

Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance

September 28, 2026 | finance.yahoo.com

Zymeworks Inc. Updates Earnings Guidance for the Year 2026

September 28, 2026 | marketscreener.comM

Zymeworks Appoints Stuart Knight as Executive Vice President & Chief Information Officer

September 28, 2026 | marketscreener.comM

Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow

September 28, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZYME, ALKS, IMVT, and KNSA Company Descriptions

Alkermes NASDAQ:ALKS

$41.22 +1.12 (+2.79%)

Closing price 04:00 PM Eastern

Extended Trading

$41.16 -0.06 (-0.16%)

As of 05:23 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Immunovant NASDAQ:IMVT

$26.73 -0.78 (-2.84%)

Closing price 04:00 PM Eastern

Extended Trading

$26.75 +0.02 (+0.07%)

As of 05:31 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$78.59 -1.35 (-1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$78.58 -0.01 (-0.01%)

As of 05:38 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Zymeworks NASDAQ:ZYME

$25.03 -0.72 (-2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$25.00 -0.03 (-0.10%)

As of 05:23 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYME, ALKS, IMVT, and KNSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYME, ALKS, IMVT, and KNSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYME, ALKS, IMVT, and KNSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZYME, ALKS, IMVT, and KNSA Company Descriptions

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYME, ALKS, IMVT, and KNSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYME, ALKS, IMVT, and KNSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYME, ALKS, IMVT, and KNSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZYME, ALKS, IMVT, and KNSA Company Descriptions

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools